Marginal zone lymphoma is a rare, slowly progressing type of non-Hodgkin lymphoma initially treated with rituximab (an anti-CD20 drug), either alone or in combination with chemotherapy. Unfortunately, many patients experience a relapse or develop resistance to these drugs. Treatment options then become limited, and alternate treatments for the lymphoma are r...
Umbralisib does not have any approved therapeutic indications.
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.